Story detail view · 2026-07
STAT+: Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug

STAT+: Ahead of hearing, FDA questions the efficacy of Capricor’s Duchenne drug

Quick Summary

Ahead of a hearing, the FDA raised questions about the benefits of a Duchenne treatment from Capricor Therapeutics, another twist for the rare disease drug.

Continue Reading on STAT News

Get instant updates on Telegram

Join our channel to receive the latest headlines and breaking stories as soon as they are published.

Join channel

Comments (0)

Join the conversation. Comments are rate-limited, secured, and GDPR-compliant.

No comments yet. Be the first to share your thoughts!

Write a comment

0 / 500